BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol 2016; 22(32): 7289-7300 [PMID: 27621575 DOI: 10.3748/wjg.v22.i32.7289] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 62] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Tajiri K, Futsukaichi Y, Kobayashi S, Nagata K, Yasumura S, Takahara T, Minemura M, Yasuda I. Efficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2019;12:2205-14. [PMID: 30988625 DOI: 10.2147/OTT.S191741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nomura T, Tani J, Deguchi A, Nakahara M, Oura K, Tadokoro T, Fujita K, Mimura S, Sakamoto T, Morishita A, Yoneyama H, Kobara H, Sanomura T, Nishiyama Y, Okano K, Suzuki Y, Takahashi S, Shibata T, Tsutsui K, Himoto T, Masaki T. Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion. Mol Clin Oncol 2019;11:447-54. [PMID: 31602300 DOI: 10.3892/mco.2019.1920] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Wu Y, Qi H, Cao F, Shen L, Chen S, Xie L, Huang T, Song Z, Zhou D, Fan W. TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma. Front Pharmacol 2020;11:1130. [PMID: 32903854 DOI: 10.3389/fphar.2020.01130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 De Robertis R, Paiella S, Cardobi N, Landoni L, Tinazzi Martini P, Ortolani S, De Marchi G, Gobbo S, Giardino A, Butturini G, Tortora G, Bassi C, D’onofrio M. Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay. Abdom Radiol 2018;43:613-9. [DOI: 10.1007/s00261-017-1243-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
5 Qadan M, Kothary N, Sangro B, Palta M. The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Am Soc Clin Oncol Educ Book 2020;40:1-8. [PMID: 32213090 DOI: 10.1200/EDBK_280811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Bai S, Wu Y, Yan Y, Li R, Kang H, Zhang J, Ma W, Gao Y, Hui B, Ma H, Zhang X, Ren J. Evaluation of the Efficacy and Toxicity of Radiotherapy for Type III-IV Portal Vein Tumor Thrombi. Technol Cancer Res Treat 2021;20:1533033821995286. [PMID: 33590809 DOI: 10.1177/1533033821995286] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Shehta A, Farouk A, Elghawalby AN, Elshobary M, Aboelenin A, Fouad A, Ali MA. Outcomes of Hepatic Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion. J Surg Res 2021;266:269-83. [PMID: 34038849 DOI: 10.1016/j.jss.2021.04.011] [Reference Citation Analysis]
8 Toesca DAS, Barry A, Sapisochin G, Beecroft R, Dawson L, Owen D, Mouli S, Lewandowski R, Salem R, Chang DT. Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:295-308. [PMID: 30309640 DOI: 10.1016/j.semradonc.2018.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen L, Zhong JH. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget 2017;8:33911-21. [PMID: 28430610 DOI: 10.18632/oncotarget.15411] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
10 Kato T, Kudo A, Kinowaki Y, Ishikawa Y, Watanabe S, Akahoshi K, Ogawa K, Ono H, Ban D, Tanaka S, Tanabe M. A novel classification of portal venous tumor invasion to predict residual tumor status after surgery in patients with pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 2021. [PMID: 33983461 DOI: 10.1007/s00432-021-03660-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kim N, You MW. Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. Jpn J Radiol 2019;37:781-92. [PMID: 31522384 DOI: 10.1007/s11604-019-00868-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Latteri S, Malaguarnera G, Catania VE, La Greca G, Bertino G, Borzì AM, Drago F, Malaguarnera M. Homocysteine Serum Levels as Prognostic Marker of Hepatocellular Carcinoma with Portal Vein Thrombosis. Curr Mol Med 2019;19:532-8. [PMID: 31187711 DOI: 10.2174/1566524019666190610120416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kow AWC. Transplantation vs liver resection in patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2019;4:33. [PMID: 31231700 DOI: 10.21037/tgh.2019.05.06] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
14 Morrell GR. Detection of Tumor Thrombus in Hepatocellular Carcinoma. Radiology 2022;302:116-7. [PMID: 34581634 DOI: 10.1148/radiol.2021211984] [Reference Citation Analysis]
15 Wang JC, Xia AL, Xu Y, Lu XJ. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. J Cell Physiol. 2019;234:1062-1070. [PMID: 30256409 DOI: 10.1002/jcp.27324] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
16 Wang EA, Stein JP, Bellavia RJ, Broadwell SR. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Int J Clin Pract 2017;71:e12972. [DOI: 10.1111/ijcp.12972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
17 Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiotherapy and Oncology 2018;129:112-22. [DOI: 10.1016/j.radonc.2017.11.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
18 Patidar Y, Mukund A, Sarin SK; Basavaraj 1. Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Tertiary Care Center Experience. Indian J Radiol Imaging 2021;31:270-6. [PMID: 34556907 DOI: 10.1055/s-0041-1734367] [Reference Citation Analysis]
19 Ryon EL, Kronenfeld JP, Lee RM, Yopp A, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Russell MC, Goel N, Merchant NB, Datta J. Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative Analysis. J Surg Oncol 2021;123:407-15. [PMID: 33125746 DOI: 10.1002/jso.26282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Bae SH, Jang WI, Park HC. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. Oncotarget. 2017;8:59965-59976. [PMID: 28938697 DOI: 10.18632/oncotarget.19219] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
21 Chan SL, Yeo W, Mo F, Chan AWH, Koh J, Li L, Hui EP, Chong CCN, Lai PBS, Mok TSK, Yu SCH. A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer 2017;123:3977-85. [PMID: 28640364 DOI: 10.1002/cncr.30825] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
22 Tao Z, Ruan Y, Peng Z, Zhang K, Gao Y. Transarterial Chemoembolization Combined With Endoscopic Therapy Is Beneficial for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices. Front Oncol 2021;11:783574. [PMID: 34926300 DOI: 10.3389/fonc.2021.783574] [Reference Citation Analysis]
23 Yuan J, Yin X, Tang B, Ma H, Zhang L, Li L, Chen R, Xie X, Ren Z. Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. Biomed Res Int 2019;2019:2141859. [PMID: 31467872 DOI: 10.1155/2019/2141859] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
24 Que J, Wu HC, Lin CH, Huang CI, Li LC, Ho CH. Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis. Medicine (Baltimore) 2020;99:e19660. [PMID: 32221093 DOI: 10.1097/MD.0000000000019660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Zhou Q, An Y, Liu T, Liu Z, Li R, Wang C, Zhou F, Liu C, Zhu K. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation. Int J Hyperthermia 2022;39:97-107. [PMID: 34979845 DOI: 10.1080/02656736.2021.2021303] [Reference Citation Analysis]
26 Cheng S, Chen M, Cai J; National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumor Thrombus. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget. 2017;8:8867-8876. [PMID: 27780939 DOI: 10.18632/oncotarget.12817] [Cited by in Crossref: 27] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
27 Takahashi K, Kim J, Takahashi A, Hashimoto S, Doi M, Furuya K, Hashimoto R, Owada Y, Ogawa K, Ohara Y, Akashi Y, Hisakura K, Enomoto T, Shimomura O, Noguchi M, Oda T. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report. World J Hepatol 2021; 13(3): 384-392 [PMID: 33815680 DOI: 10.4254/wjh.v13.i3.384] [Reference Citation Analysis]
28 Malaguarnera G, Catania VE, Latteri S, Borzì AM, Bertino G, Madeddu R, Drago F, Malaguarnera M. Folate levels in hepatocellular carcinoma patients with portal vein thrombosis. BMC Gastroenterol 2020;20:375. [PMID: 33172390 DOI: 10.1186/s12876-020-01525-3] [Reference Citation Analysis]
29 Luo N, Li W, Xie J, Fu D, Liu L, Huang X, Su D, Jin G. Preoperative normalized iodine concentration derived from spectral CT is correlated with early recurrence of hepatocellular carcinoma after curative resection. Eur Radiol 2021;31:1872-82. [PMID: 33037444 DOI: 10.1007/s00330-020-07330-6] [Reference Citation Analysis]
30 Lin T, Lin Z, Mai P, Zhang E, Peng L. Identification of prognostic biomarkers associated with the occurrence of portal vein tumor thrombus in hepatocellular carcinoma. Aging (Albany NY) 2021;13:11786-807. [PMID: 33878734 DOI: 10.18632/aging.202876] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Li S, Li L, Li B, Wang W. Safety and efficacy of endovascular implantation of a portal vein stent combined with iodine-125 seed-strips followed by transcatheter arterial chemoembolization with sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis. Br J Radiol 2020;93:20190279. [PMID: 32464068 DOI: 10.1259/bjr.20190279] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Kuo F, Cheng T, Cheng Y, Wu C, Wang C. Effectiveness of multimodality treatment for hepatocellular carcinoma patients with portal vein thrombosis: A real world experience. Adv in Digestive Med. [DOI: 10.1002/aid2.13275] [Reference Citation Analysis]
33 Tihanyi DK, Szijarto A, Fülöp A, Denecke B, Lurje G, Neumann UP, Czigany Z, Tolba R. Systematic Review on Characteristics and Reporting Quality of Animal Studies in Liver Regeneration Triggered by Portal Vein Occlusion and Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy: Adherence to the ARRIVE Guidelines. J Surg Res 2019;235:578-90. [PMID: 30691845 DOI: 10.1016/j.jss.2018.10.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Fan W, Yuan G, Fan H, Li F, Wu Y, Zhao Y, Yao W, Wang Y, Xue M, Yang J, Li J. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Clin Ther 2019;41:1463-76. [PMID: 31303279 DOI: 10.1016/j.clinthera.2019.04.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
35 Shen L, Xi M, Zhao L, Zhang X, Wang X, Huang Z, Chen Q, Zhang T, Shen J, Liu M, Huang J. Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib. Cancers (Basel) 2018;10:E516. [PMID: 30558224 DOI: 10.3390/cancers10120516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
36 Feng X, Jiang T, Yang C, Pang S, Ding Z, Hu H, Wang H, Dong L, Yang N. RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding. Cell Death Dis 2021;13:6. [PMID: 34921137 DOI: 10.1038/s41419-021-04447-4] [Reference Citation Analysis]
37 Yin J, Bo WT, Sun J, Xiang X, Lang JY, Zhong JH, Li LQ. New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol. 2017;5:169-176. [PMID: 28660155 DOI: 10.14218/jcth.2016.00071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
38 Zhang ZY, Zhang EL, Zhang BX, Chen XP, Zhang W. Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: A comprehensive review. World J Gastrointest Surg 2021; 13(8): 796-805 [PMID: 34512903 DOI: 10.4240/wjgs.v13.i8.796] [Reference Citation Analysis]
39 Jang TY, Huang CI, Yeh ML, Lin ZY, Chen SC, Chuang WL. The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis. Medicine (Baltimore) 2019;98:e15066. [PMID: 30921239 DOI: 10.1097/MD.0000000000015066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Lin J, Jiang H, Yang W, Jiang N, Zheng Q, Huang N, Wang X, Li A, Huang J. Predictive factors of benefit from iodine-125 brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis. Brachytherapy. 2018;pii:S1538-4721(18)30424-0. [PMID: 30467014 DOI: 10.1016/j.brachy.2018.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Liu YH, Lo EYJ, Lee KF, Chong CCN, Lai PBS. An unusual cause of upper gastrointestinal bleeding due to recurrent hepatocellular carcinoma: A case report. Int J Surg Case Rep 2020;70:83-6. [PMID: 32416488 DOI: 10.1016/j.ijscr.2020.04.008] [Reference Citation Analysis]
42 Korhan P, Yılmaz Y, Bağırsakçı E, Güneş A, Topel H, Carr BI, Atabey N. Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:7568742. [PMID: 30425976 DOI: 10.1155/2018/7568742] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Cao Y, Ding W, Zhang J, Gao Q, Yang H, Cao W, Wang Z, Fang L, Du R. Significant Down-Regulation of Urea Cycle Generates Clinically Relevant Proteomic Signature in Hepatocellular Carcinoma Patients with Macrovascular Invasion. J Proteome Res 2019;18:2032-44. [DOI: 10.1021/acs.jproteome.8b00921] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
44 Zhang L, Zhong B, Hu B, Li W, Huang P, Zhang S, Song J, Ji J, Ni C. Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy. J Interv Med 2020;3:201-7. [PMID: 34805935 DOI: 10.1016/j.jimed.2020.08.001] [Reference Citation Analysis]
45 Guo JH, Liu SX, Gao S, Kou FX, Zhang X, Wu D, Li XT, Chen H, Wang XD, Liu P, Zhang PJ, Xu HF, Cao G, Zhu LZ, Yang RJ, Zhu X. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. World J Gastroenterol 2020; 26(27): 3975-3988 [PMID: 32774071 DOI: 10.3748/wjg.v26.i27.3975] [Reference Citation Analysis]
46 Liu B, Xiong T, Lu J, Li S, Bai X, Zhou F, Wu Q. Technical note: A fast and accurate analytical dose calculation algorithm for 125 I seed-loaded stent applications. Med Phys 2021;48:7493-503. [PMID: 34482556 DOI: 10.1002/mp.15207] [Reference Citation Analysis]
47 Zhou W, Fang DL, He Y. Screening potential prognostic biomarkers for portal vein emboli in patients with hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1927-38. [PMID: 34532139 DOI: 10.21037/jgo-21-433] [Reference Citation Analysis]
48 Yuan G, Cheng X, Li Q, Zang M, Huang W, Fan W, Wu T, Ruan J, Dai W, Yu W, Chen M, Guo Y, Hu X, Chen J. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Onco Targets Ther 2020;13:12683-93. [PMID: 33328740 DOI: 10.2147/OTT.S286169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
49 Lu J, Zhang X, Zhong B, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng S, Teng G. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019;4:721-30. [DOI: 10.1016/s2468-1253(19)30178-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
50 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T, Zhang B, Wu J, Li Q, Hu Q, Shen L, Bai X, Liang T, Wei Q. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol 2018;13:188. [PMID: 30253783 DOI: 10.1186/s13014-018-1136-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
52 Lee SJ, Kim M, Kwak YK, Kang HJ. MRI-guided radiotherapy for PVTT in HCC patients: evaluation of the efficacy and safety. J Cancer Res Clin Oncol 2021. [PMID: 34490584 DOI: 10.1007/s00432-021-03788-z] [Reference Citation Analysis]
53 Song X, He Y, Liang H, Han M, Shao Z. INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus. BMC Surg 2020;20:174. [PMID: 32738882 DOI: 10.1186/s12893-020-00836-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Zhao W, Qiu L, Liu H, Xu Y, Zhan M, Zhang W, Xin Y, He X, Yang X, Bai J, Xiao J, Guan Y, Li Q, Chang L, Yi X, Li Y, Chen X, Lu L. Circulating tumor DNA as a potential prognostic and predictive biomarker during interventional therapy of unresectable primary liver cancer. J Gastrointest Oncol 2020;11:1065-77. [PMID: 33209498 DOI: 10.21037/jgo-20-409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Nakamura M, Ito K, Takemura N, Mihara F, Kokudo N. Hepatectomy for liver metastases from cervical cancer with portal vein tumor thrombosis: a case report. Clin J Gastroenterol 2022. [PMID: 35192190 DOI: 10.1007/s12328-022-01603-x] [Reference Citation Analysis]
56 Srivastava A, Parambath HK, Ramdulari AV, Saxena H, Kumar R, Pandey S, Shalimar, Gupta S, Jee B. Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy? Int J Radiat Biol 2022;:1-15. [PMID: 35311612 DOI: 10.1080/09553002.2022.2055800] [Reference Citation Analysis]
57 Wang Y, Shen J, Feng S, Liang R, Lai J, Li D, Peng B, Wang Z, Huang C, Kuang M. Hepatic resection versus transarterial chemoembolization in infiltrative hepatocellular carcinoma: A multicenter study. J Gastroenterol Hepatol 2020;35:2220-8. [PMID: 32246889 DOI: 10.1111/jgh.15060] [Reference Citation Analysis]
58 Esposito P, Matteo M, Concepcion C, Montanarella M, Matteo J. Portal Vein Tumor Thrombus: No Longer a Death Sentence. Cureus 2021;13:e12845. [PMID: 33628697 DOI: 10.7759/cureus.12845] [Reference Citation Analysis]
59 Sun X, Zhang Q, Mei J, Yang Z, Chen M, Liang T. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09405-7] [Reference Citation Analysis]
60 Cao F, Shen L, Qi H, Xie L, Song Z, Chen S, Fan W. Tree-based classification system incorporating the HVTT-PVTT score for personalized management of hepatocellular carcinoma patients with macroscopic vascular invasion. Aging (Albany NY) 2019;11:9544-55. [PMID: 31682230 DOI: 10.18632/aging.102403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
61 Qiu Z, Wang G, Yan H, Qi H, Zuo M, Wang G, Jiang W, Chen Z, Xue J, Lu L, Zhang F, Gao F. TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension. Eur Radiol 2022. [PMID: 35441840 DOI: 10.1007/s00330-022-08705-7] [Reference Citation Analysis]
62 Thompson SM, Wells ML, Andrews JC, Ehman EC, Menias CO, Hallemeier CL, Roberts LR, Venkatesh SK. Venous invasion by hepatic tumors: imaging appearance and implications for management. Abdom Radiol (NY) 2018;43:1947-67. [PMID: 28929197 DOI: 10.1007/s00261-017-1298-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
63 Sotiropoulos C, Thomopoulos K. Non-Traumatic Intramuscular Hip Hematoma in a Cirrhotic Patient With Hepatocellular Carcinoma and Portal Vein Thrombosis Treated With Sorafenib and Low Molecular Weight Heparin. Cureus 2021;13:e14818. [PMID: 34094772 DOI: 10.7759/cureus.14818] [Reference Citation Analysis]
64 Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer 2020;9:28-40. [PMID: 32071907 DOI: 10.1159/000503685] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
65 Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019; 25(31): 4360-4382 [PMID: 31496618 DOI: 10.3748/wjg.v25.i31.4360] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 20] [Article Influence: 9.7] [Reference Citation Analysis]
66 Quencer KB, Friedman T, Sheth R, Oklu R. Tumor thrombus: incidence, imaging, prognosis and treatment. Cardiovasc Diagn Ther 2017;7:S165-77. [PMID: 29399520 DOI: 10.21037/cdt.2017.09.16] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
67 Xu F, Zhang L, He W, Song D, Ji X, Shao J. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients. Dis Markers 2021;2021:8868370. [PMID: 33628341 DOI: 10.1155/2021/8868370] [Reference Citation Analysis]
68 Iwamoto H, Nomiyama M, Niizeki T, Shimose S, Shirono T, Nakano M, Satani M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Kuromatsu R, Ogo E, Abe T, Tanaka M, Koga H, Torimura T. Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy. Oncology 2019;96:192-9. [PMID: 30650415 DOI: 10.1159/000495568] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
69 Wu K, Shui Y, Sun W, Lin S, Pang H. Utility of Radiomics for Predicting Patient Survival in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With Stereotactic Body Radiotherapy. Front Oncol 2020;10:569435. [PMID: 33178598 DOI: 10.3389/fonc.2020.569435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Chauhan N, Bukovcan J, Boucher E, Cosgrove D, Edeline J, Hamilton B, Kulik L, Master F, Salem R. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR Res Protoc 2018;7:e11234. [PMID: 30111528 DOI: 10.2196/11234] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
71 Sun H, Zhang M, Liu R, Liu Y, Hou Y, Wu C. Endovascular implantation of 125I seed combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. Future Oncol. 2018;14:1165-1176. [PMID: 29334777 DOI: 10.2217/fon-2017-0354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
72 Bae JS, Lee JM, Jeon SK, Yoo J, Park SJ, Yoon JH, Joo I, Lee KB, Kim H. LI-RADS Tumor in Vein at CT and Hepatobiliary MRI. Radiology 2021;:210215. [PMID: 34581625 DOI: 10.1148/radiol.2021210215] [Reference Citation Analysis]
73 Guarino M, Cucchetti A, Pontillo G, Farinati F, Benevento F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Rodolfo S, Cabibbo G, Marra F, Mega A, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F, Giannini EG, Morisco F; ITA.LI.CA Group. Pattern of macrovascular invasion in hepatocellular carcinoma. Eur J Clin Invest 2021;51:e13542. [PMID: 33755196 DOI: 10.1111/eci.13542] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Liu Y, Xue D, Zhang X, Gao F, Sun L, Yang X, Li Y, Zhang Q, Zhu B, Niu S, Huang Y, Hu Y, Wang X. Nomogram for Individualized Prediction of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis on Conservative Treatment. Biomed Res Int 2020;2020:1473718. [PMID: 32149077 DOI: 10.1155/2020/1473718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Ishihara A, Deguchi A, Arai H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Aino H, Matsukuma N, Matsugaki S, Ogata K, Yano Y, Ueno T, Kajiwara M, Itano S, Fukuizumi K, Kawano H, Noguchi K, Tanaka M, Yamaguchi T, Kuromatsu R, Kawaguchi A, Koga H, Torimura T, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan. Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. Cancers (Basel) 2021;13:646. [PMID: 33562793 DOI: 10.3390/cancers13040646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
76 Kong XQ, Dong YP, Wu JX, He JY, Le YY, Du KX, Peng QQ, Li JL. High-biologically effective dose palliative radiotherapy for a tumor thrombus might improve the long-term prognosis of hepatocellular carcinoma: a retrospective study. Radiat Oncol 2017;12:92. [PMID: 28569169 DOI: 10.1186/s13014-017-0831-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
77 Jung S, Shen S, Ye SJ. Dose perturbation and inhomogeneity of multi-arrays of 125I seed-loaded stent for treatment of portal vein tumor thrombosis. Phys Med 2019;66:1-7. [PMID: 31563726 DOI: 10.1016/j.ejmp.2019.09.077] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Boraschi P, Tarantini G, Pacciardi F, Donati F. Dynamic and Multi-phase Contrast-Enhanced CT Scan. In: Radu-ionita F, Pyrsopoulos NT, Jinga M, Tintoiu IC, Sun Z, Bontas E, editors. Liver Diseases. Cham: Springer International Publishing; 2020. pp. 479-91. [DOI: 10.1007/978-3-030-24432-3_42] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Tao ZW, Cheng BQ, Zhou T, Gao YJ. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00229-0. [PMID: 34955380 DOI: 10.1016/j.hbpd.2021.12.004] [Reference Citation Analysis]
80 Iwaki K, Kaido T, Yamamoto G, Kamo N, Yagi S, Taura K, Uemoto S. Mass-forming intrahepatic cholangiocarcinoma with portal vein tumor thrombus and bile duct tumor thrombus: A case report. Int J Surg Case Rep 2017;40:13-6. [PMID: 28917216 DOI: 10.1016/j.ijscr.2017.08.059] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
81 Ohya Y, Hayashida S, Tsuji A, Kuramoto K, Shibata H, Setoyama H, Hayashi H, Kuriwaki K, Sasaki M, Iizaka M, Nakahara O, Inomata Y. Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy. Surg Case Rep 2020;6:318. [PMID: 33301055 DOI: 10.1186/s40792-020-01078-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 Filippi L, Di Costanzo GG, D’agostini A, Tortora R, Pelle G, Cianni R, Schillaci O, Bagni O. Decrease in total lesion glycolysis and survival after yttrium-90-radioembolization in poorly differentiated hepatocellular carcinoma with portal vein tumour thrombosis. Nuclear Medicine Communications 2018;39:845-52. [DOI: 10.1097/mnm.0000000000000879] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
83 Sun T, Chen L, Kan X, Ren Y, Cao Y, Zhang W, Lu H, Zheng C. A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Oncol 2022;2022:1255133. [PMID: 35356254 DOI: 10.1155/2022/1255133] [Reference Citation Analysis]